In conclusion, in this study we have generated novel human and murine CLL and Richter Syndrome model systems to show that malignant cells with truncation mutations in NFKBIE are selected by growth signals provided by the tumor microenvironment, that such cells can impact the anti-tumor immune response and that such mutations can impart resistance to ibrutinib therapy. This evidence concerns the gene NFKBIE and neoplasm.